1 recruiting, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow alrizomadlin: new trials by email Literature Review of alrizomadlin trials Research Report on alrizomadlin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma alrizomadlin - Mesothelioma, Malignant Mesothelioma (MM) | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-03-16 | 2026-03-17 |
Mesothelioma (1) · Mesothelioma, Malignant (1) · Neurofibromatosis 1 (1) · Neurofibrosarcoma (1)
AeRang Kim (1) · National Cancer Institute (NCI) (1)
United States (2)
AeRang Kim, MD, PhD (1) · David S Schrump, M.D. (1)